A phase I/Ib multicenter study has evaluated the MTD, safety, and pharmacokinetics of BEZ235, an oral dual PI3K/mTOR inhibitor, when used as monotherapy or in combination with trastuzumab in patients with advanced solid tumors, including HER2‐positive advanced breast cancer (aBC). This evidence concerns the gene PIK3CG and breast cancer.